With over 25 years of experience in supply chain transformation, can you share a bit about your career journey and what inspired you to focus on building resilient supply chains in collaboration with some of the world’s largest and most successful companies?

"Over the past 25 years, my journey has evolved from optimizing individual supply chain functions to orchestrating decisions across the enterprise-working with organizations ranging from under a billion to 100+ billion in scale.

Early in my career, the focus was heavily on cost and efficiency. But over time, especially during periods of disruption, I saw how those highly optimized models often struggled to adapt.

I usually describe supply chains not as systems that should avoid stress, but more like a spring or a power grid: they need to absorb disruption, reroute intelligently, and return to equilibrium. The goal is not just efficiency, but balance.

For example:

 In one organization, aggressive cost optimization led to single-supplier dependency, which worked well until a disruption exposed the fragility. In another, a more balanced approach-dual sourcing and strategic buffers-allowed the organization to recover in days instead of weeks. 

That shift-from efficiency to resilience, and ultimately to balance-has really shaped how I approach supply chain transformation today.

Throughout your career, you’ve guided C-suite executives through complex supply chain challenges. What has been the most rewarding transformation project you’ve led, and how did it create long-term value for the organization?

One of the most rewarding transformations I've led was helping a global organization, anticipating significant growth, move from what I call "individual brilliance" to a process-driven, scalable supply chain model.

Very often, you see highly capable individuals or strong functional teams, but collectively the system doesn't perform at the same level. The real challenge is not capability-it's coordination.

Success came from two things:

 First, placing the right capabilities at the right decision points across the supply chain. Second, pacing the transformation at a speed the organization could absorb-because transformation only works if the organization can carry it forward. 

But the real value wasn’t just efficiency—it was enabling the organization to operate as one coordinated system, rather than a collection of high-performing parts.”

You’re passionate about using AI to address supply chain challenges. How do you see technologies like predictive and artificial intelligence and digital twins revolutionizing pharmaceutical supply chains, and what excites you most about their potential?

Pharmaceutical supply chains are inherently complex-there are a large number of variables, from demand variability and regulatory constraints to supplier dependencies. But the real challenge is not just the number of variables-it's the scale of data and how we translate that into effective decisions.

That's where AI and digital twins become powerful enablers. I often describe it as turning the supply chain into a living system-one that continuously senses, analyzes, and adapts.

For example:

 AI can detect early demand shifts or supply risks, enabling organizations to adjust production or sourcing before issues materialize, while also helping contextualize vast amounts of data into actionable insights. Digital twins allow us to simulate disruptions-such as a supplier outage or capacity constraint-and determine the optimal response across manufacturing, inventory, and distribution. 

What excites me most is the convergence of these capabilities-connecting signals, decisions, and execution-so supply chains become not just more efficient, but truly adaptive and resilient. In pharma, that directly translates to ensuring continuity of supply and better patient outcomes."

Having worked with some of the world’s largest companies, what common supply chain risks do you see across industries, and how can pharmaceutical companies adapt strategies from other sectors to strengthen their networks?

"Across industries, I consistently see three common risks: fragmentation in how decisions are made, over-optimization for cost at the expense of resilience, and limited real-time visibility and decision speed.

These challenges become even more pronounced in pharmaceutical supply chains due to the level of complexity, regulatory requirements, and the scale of data involved.

At the core, it comes back to balance-between efficiency, resilience, and service. When organizations optimize too heavily for one dimension, the system becomes fragile under disruption.

There are strong lessons pharma can draw from other industries:

 In automotive, organizations have invested in multi-tier supplier visibility and scenario-based planning, allowing them to assess risk across the network and respond more proactively to disruptions. 

In consumer goods, companies have advanced demand sensing using real-time signals-such as POS data, weather, and promotions-combined with integrated control towers, enabling faster, more coordinated decision-making across functions. 

In pharma, the opportunity is to combine these industry practices with AI-driven and agentic capabilities-moving from visibility to decision orchestration-so organizations can respond faster, more coherently, and ultimately ensure continuity of supply."

Your session at CPHI Americas will explore how digital transformation can turn fragility into strength. What are the top actionable insights attendees can expect to gain from your discussion?

"I would highlight three key takeaways.

 First, move from visibility to decision orchestration-dashboards alone don't drive outcomes; the real value comes from enabling faster, more coordinated decisions across the supply chain. Second, prioritize targeted investments that deliver near-term value, rather than large, multi-year transformations that take too long to realize impact. Third, design supply chains for balance-not just cost or efficiency, but resilience and service as well. 

Ultimately, the goal is to build a system that performs efficiently under normal conditions but can also adapt and recover quickly under stress."

As supply chains become increasingly dynamic ecosystems, what emerging trends or technologies do you believe will shape the next decade of supply chain transformation, particularly in the pharmaceutical industry?

"Looking ahead, I see four key trends shaping the next decade of supply chain transformation—especially in pharmaceuticals.

First, Agentic AI will move supply chains toward more autonomous operations - Not just generating insights, but continuously monitoring signals, recommending actions, and increasingly participating in cross-functional decision-making. Second, the expansion of IoT and edge computing will dramatically increase real-time visibility. With connected devices across manufacturing, cold chain, and logistics, decisions can be made closer to where events occur—improving speed and precision. Third, quantum computing will unlock new possibilities in solving highly complex supply chain problems. Particularly in pharma, where optimization across manufacturing, inventory, and distribution involves thousands of variables, quantum can significantly accelerate scenario evaluation and decision-making. Fourth, we will see a shift toward orchestrated ecosystems. Supply chains will no longer operate as isolated functions, but as connected networks—where decisions across planning, procurement, manufacturing, and logistics are coordinated in real time. 

Across all of this, the goal remains the same—building supply chains that are balanced, adaptive, and resilient. In pharma, that ultimately means ensuring continuity of supply while maintaining the highest standards of quality and compliance."